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Background: Chronic heart failure (HF) disease management programs have reported inconsistent results and have
not included comorbid depression management or specifically focused on improving patient-reported outcomes.
The Patient Centered Disease Management (PCDM) trial was designed to test the effectiveness of collaborative care
disease management in improving health status (symptoms, functioning, and quality of life) in patients with HF
who reported poor HF-specific health status.
Methods/design: Patients with a HF diagnosis at four VA Medical Centers were identified through population-
based sampling. Patients with a Kansas City Cardiomyopathy Questionnaire (KCCQ, a measure of HF-specific health
status) score of < 60 (heavy symptom burden and impaired quality of life) were invited to enroll in the PCDM trial.
Enrolled patients were randomized to receive usual care or the PCDM intervention, which included: (1) collaborative
care management by VA clinicians including a nurse, cardiologist, internist, and psychiatrist, who worked with
patients and their primary care providers to provide guideline-concordant care management, (2) home
telemonitoring and guided patient self-management support, and (3) screening and treatment for comorbid
depression. The primary study outcome is change in overall KCCQ score. Secondary outcomes include depression,
medication adherence, guideline-based care, hospitalizations, and mortality.
Discussion: The PCDM trial builds on previous studies of HF disease management by prioritizing patient health
status, implementing a collaborative care model of health care delivery, and addressing depression, a key barrier to
optimal disease management. The study has been designed as an ‘effectiveness trial’ to support broader
implementation in the healthcare system if it is successful.
Trial registration: Unique identifier: NCT00461513
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Despite advances in chronic heart failure (HF) therapies,
HF is a leading cause of disability, hospitalization, and
death in the United States [1]. Moreover, HF has a major
impact on patients’ health status, including their symp-
tom burden (e.g. dyspnea), functional status, and health-
related quality of life. However, few HF interventions* Correspondence: david.bekelman@va.gov
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reproduction in any medium, provided the orhave specifically targeted these critical patient-centered
outcomes. In addition, diminished patient health status
is predictive of HF hospitalization, mortality, and re-
source utilizations, yet health status has not been used
to screen for patients to target disease management in-
terventions [2].
While disease management has been variously defined
and implemented, some previous studies have reported
that HF disease management can reduce rates of hos-
pitalization, and a few have demonstrated reductions in
mortality, reductions in cost, or improvements in quality
of life. However, many of these studies have been small,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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between disease management and improved outcomes has
been inconsistent [3-6]. Many HF disease-management
studies to date have relied solely on nurse case manage-
ment rather than multidisciplinary collaborative care, have
not leveraged health information technology, and/or have
had a limited focus on patient self-care. Most have not in-
cluded screening and treatment of comorbid depression,
or specifically targeted improvement in patient health sta-
tus as the primary outcome [7]. The Patient-Centered Dis-
ease Management (PCDM) trial was designed to address
these limitations.
The PCDM trial is evaluating the effectiveness of a
collaborative care intervention with telemonitoring and
evidence-based HF and depression management in an
at-risk population of HF patients with diminished health
status. All HF patients from participating centers were
identified using existing VA electronic health record
databases. The primary outcome of the PCDM trial is
1-year change in patient-reported HF health status, mea-
sured using the Kansas City Cardiomyopathy Question-
naire (KCCQ), comparing patients randomized to usual
care versus the PCDM intervention. Secondary out-
comes include depression, adherence to guideline-based
therapies, hospitalizations, and mortality.
Methods/design
Study design overview
The primary objective of the PCDM trial is to determine
whether a collaborative care HF disease management
intervention, including depression assessment and treat-
ment, improves patient-reported health status between
baseline and 12 months, as measured by the KCCQ. The
study was funded by the United State Department of
Veterans Affairs (VA) and conducted in four VA medical
centers across the U.S. The VA’s comprehensive elec-
tronic medical record was used to identify potential par-
ticipants for the study. All patients with HF at the four
sites were screened with the KCCQ. Eligible patients
with diminished heart failure-specific health status
(KCCQ summary score <60) were invited to an enroll-
ment visit. Patients provided informed consent, were
randomized to the PCDM intervention or usual care,
and were followed for a 12-month period. The study was
approved by the Institutional Review Boards at each of
the study sites.
Conceptual framework
The conceptual framework for the PCDM intervention
highlights HF as a chronic illness often accompanied by
co-occurring depression, both of which are prime candi-
dates for disease management approaches, and the
importance of health information technology, self-
management, and health status outcomes. The ChronicCare Model [8] combines patient self-management sup-
port with health system change to achieve productive in-
teractions between a “proactive health care team” and an
“activated patient”, producing improved functional and
clinical outcomes. The PCDM intervention uses collab-
orative care as the primary health system change. Col-
laborative care is the use of multidisciplinary teams to
deliver evidence-based treatment to a defined population
of patients with chronic illness [9]. The intervention
aims to activate patients by promoting self-management
of HF and depression through home telemonitoring and
education, and when indicated, through integrating
depression care into chronic illness care [10]. While
telemonitoring in isolation is not effective in improving
mortality or hospitalization, [11] telemonitoring might
be a useful adjunct to the collaborative care model of
health care delivery.
Setting and population
The study is being conducted at the Denver, Palo Alto,
Richmond, and Seattle VA Medical Centers and their
affiliated community-based outpatient clinics. All pa-
tients with an assigned primary care provider and at
least one primary care provider visit during the prior
12 months with a HF diagnosis code in the VA elec-
tronic health record were screened for eligibility to par-
ticipate (see Figure 1 for study population flow).
The study was purposefully designed to target patients
with a diagnosis of HF in the VA electronic health rec-
ord, irrespective of type of heart failure (e.g. with or
without preserved left ventricular systolic function). Ac-
cordingly, the diagnosis of HF was defined as meeting
any one of the following five criteria: (1) A primary in-
patient hospital discharge diagnosis of HF (ICD-9 code
428.XX); (2) ≥2 secondary inpatient hospital discharge
diagnoses of HF (ICD-9 codes 428.XX) and a primary
inpatient hospital discharge diagnosis related to heart
disease (ICD-9 codes 410.XX, 412.XX, 413.XX, 414.XX);
(3) ≥3 secondary inpatient hospital discharge diagnosis
codes related to HF; (4) ≥2 outpatient visit diagnoses of
HF, excluding emergency department visits; (5) ≥2 sec-
ondary inpatient hospital discharge diagnoses of HF
and ≥ 1 outpatient HF diagnosis. This case-finding meth-
odology has been previously described [12]. The primary
care provider of each patient was contacted by mail to
inform them of the PCDM trial and to allow them to
withdraw their patient from further consideration if they
deemed the patient to be a poor candidate for study
participation.
Recruitment and study subjects
Following the process of patient identification described
above, all remaining patients were mailed a study infor-
mational sheet, a decline-to-participate postcard, and a
Patient Identification
VA patients with primary/secondary 
diagnosis codes of HF and VA primary 
care visit during past year
Patient Recruitment
Eligible patients with poor health 
status (Kansas City Cardiomyopathy 
Questionnaire Overall Score < 60)
Baseline Visit
Consent/Randomization
Usual Care PCDM Intervention







Phone surveys at 
3, 6 months
Final Visit at 
12 months
Figure 1 Patient-centered disease management (PCDM) for
heart failure trial study population flow.
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two weeks received a reminder letter, followed by a
phone call if necessary. All returned KCCQ question-
naires were scored, and the individuals scoring < 60 were
invited to an enrollment visit if they did not meet any of
the exclusion criteria. The exclusion criteria included:
(1) cognitive or psychiatric impairment that precludes
completion of questionnaires; (2) current residence in a
nursing home; (3) irreversible, non-cardiac medical con-
ditions (e.g. metastatic cancer) likely to affect 6-month
survival or ability to execute the study protocol; (4) ab-
sence of a telephone line in the home; (5) inability to read
English; (6) prior heart transplantation; (7) Alcohol Use
Disorders Identification Test (AUDIT-C) score ≥ 7 [13].Randomization
At the enrollment visit, patients provided informed con-
sent, completed baseline survey measures, and were then
randomized. The random allocation sequence was com-
puter generated (SAS version 9.1 procedure PLAN)
using a uniform fixed randomization design with an allo-
cation ratio of 1:1 and stratification by site.Intervention
Collaborative care
The collaborative care team at each site consisted of a
local primary care provider, cardiologist, psychiatrist,
and nurse coordinator (registered nurse). The team
assessed each intervention patient through a review of
the VA electronic health record and baseline depression
scores from the Patient Health Questionnaire-9 (PHQ-9).
The team recommended care changes, as indicated, for
a given patient in accordance with the ACC/AHA
Guidelines for the Management of Chronic Heart Fail-
ure [14] and depression care and telemonitoring data as
described below. Collaborative care team recommenda-
tions were entered into a progress note in the electronic
medical record for review and co-signature by the pa-
tient’s primary care provider. Unsigned orders were
placed for primary care providers to review and sign at
their discretion. This methodology was successfully
used within the VA in a study of collaborative care for
patients with angina [15].
Screening and treatment of depression
Patients were screened for depression at the initial base-
line visit using the PHQ-9. Patients who scored ≥ 10
who were randomized to the intervention were entered
into the depression care component of the intervention,
adapted from a successful collaborative depression care
intervention [16]. This included: (1) up to 11 sessions
behavioral activation and antidepressant management
provided by the nurse coordinator and supervised by the
team psychiatrist, with approximately half of visits
planned to be by phone and half in person; (2) a depres-
sion educational video; (3) depression assessment and
self-management education via telemonitoring. The
nurse coordinator from each site participated in a two-
day training on depression and behavioral activation by
the lead study psychiatrist and four weekly follow up
calls with the lead psychiatrist. Thereafter, the nurse was
supervised by the site psychiatrist with as needed calls
with the lead psychiatrist.
Telehealth: telemonitoring and patient self-care support
Intervention patients received daily telemonitoring using
equipment that has modules for both HF and depres-
sion. The system collected blood pressure, pulse, weight,
and self-reported symptoms. Patients were asked a pre-
programmed series of questions such as, “Are you more
short of breath than usual today?”; “Do you have any
new or any more swelling than usual in your feet or an-
kles today?” Patients in the depression care component
of the intervention were asked questions about their
mood and behavior. Follow-up questions may be gener-
ated using branching-chain logic. For instance, a patient
responding that he/she is experiencing shortness of
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set for notification of the nurse coordinator or for the pa-
tient to call the nurse coordinator. The nurse coordinator
reviewed the telemonitoring data and could then either
provide counseling to the patient or present the patient to
the collaborative care team for recommendations.
The self-care programs included medication reminders
to promote adherence, education about HF and depres-
sion, medication monitoring, and dietary advice. Patients
were also taught signs and symptoms to report and ways
to manage HF and cardiovascular risk factors such as
proper technique and importance of daily self-weighing,
adherence to a low sodium diet and medication regi-
mens, and recognition of early signs and symptoms of
HF decompensation.Usual care
Patients randomized to the usual care arm continued to
receive care from their regular medical providers. This
care was fully at the discretion of the patient’s regular
clinicians, and thus may or may not have included cardi-
ology or mental health clinic care in addition to primary
care. Telemonitoring was offered to usual care patients
if they were referred for home telemonitoring by any of
their providers. However, the telemonitoring data was
handled as part of usual care by VA telemonitoring
nurses at each facility, rather than being provided to the
collaborative care team in the PCDM intervention. At
the enrollment visit, patients randomized to the usual
care arm were given information sheets that describe
self-care for HF and were provided with a scale if
needed. Primary care providers were notified if usual
care patients screened positive for depressive symptoms
based on the initial study surveys. From there, patients’
primary care clinicians assumed responsibility for de-
pression care or referral, at their discretion.Table 1 Patient-centered disease management (PCDM) for he
Domain Measure
Primary Outcome





Guideline-Based Care Criteria mapping
Hospitalizations, mortality Medical Record Review, Self- or Surrogate R
* Kansas City Cardiomyopathy questionnaire.
† Patient health questionnaire-9.
‡ Hopkins symptom checklist-20.
§ Proportion of days covered.Outcome measures
The questionnaires and methods used to measure the
study outcomes are listed in the Table 1 Baseline mea-
sures were collected in person, a research assistant (who
was blinded to the randomization arm) collected 3 and
6 month follow-up study outcome measures by phone
or in person, and the nurse coordinator collected out-
come measures at 12 months.
The primary outcome, HF-specific health status, was
measured using the KCCQ. The KCCQ is valid, reliable,
sensitive to clinical change, and predicts hospitalization
and mortality [2,17,18]. For the secondary outcomes,
depression was measured using the PHQ-9 and the
Hopkins Symptom Checklist-20 (SCL-20). The PHQ-9 is
a valid and reliable instrument that provides a continu-
ous measure of depressive symptoms [19]. The Hopkins
Symptom Checklist-20 (SCL-20) is also a valid and reli-
able measure of depression symptoms [20]. To examine
medication adherence, the proportion of days covered
(PDC) will be calculated for each patient using
established methods, based on the total number of days
supplied for filled prescriptions over the observation
time interval [21]. Primary medications to be evaluated
will be angiotensin converting enzyme inhibitors, angio-
tensin II receptor blockers, beta-blockers, aldosterone
antagonists, statins, digoxin, diuretics, and antidepres-
sants. For a given patient, the proportion of guideline-
concordant care will be determined using criteria mapping
[15,22]. The guideline-concordant care analysis will be
restricted to those patients who have a guideline indica-
tion for a medication class, such as beta-blockers for HF
with left ventricular systolic dysfunction. Hospitaliza-
tions and mortality will be assessed through VA data-
bases, supplemented by patient self-report. Vital status
will also be ascertained via the VA Vital Status File
which has a sensitivity of 98.3% and specificity of 99.8%
compared to the National Death Index [23].art failure trial study outcomes
Timing
Baseline 3-month 6-month 12-month
X X X X
X X X X
X X
X X X X
X X
eport X
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The primary hypothesis of this study is that HF patients
receiving the PCDM intervention will have improved
health status over a 12-month follow-up period com-
pared with those receiving usual care. The minimal clin-
ically meaningful difference in KCCQ summary scores is
5 points, [18] and the standard deviation of change in
KCCQ scores was estimated to be between 15 and 20
based on previous work [17,18]. Using a type I error rate
(α) of 0.05, and an attrition rate of 30%, we originally es-
timated enrollment of 600 patients would have >80%
power to detect a difference in KCCQ scores of ≥ 5
points assuming a standard deviation of 18. The data to
date showed less than 20% attrition and a KCCQ stand-
ard deviation of 15 points. With the final enrollment of
392 patients, we will have over 80% power to detect a 5
point difference in KCCQ score.
Analyses
All primary and secondary analyses will be conducted
using an intention-to-treat approach. Patients will be
analyzed in the arm to which they were randomized irre-
spective of treatment adherence. The baseline character-
istics of patients will be summarized by study group and
examined for differences. To examine the primary out-
come, change in HF-specific health status as measured
by the KCCQ, a likelihood-based random effects model
using all available data will be implemented [24]. We will
examine the magnitude and patterns of missing data to
check the sensitivity of the model assumptions. Model
parameters will be estimated using the SAS procedure
MIXED (SAS Institute, Cary, NC). Most of the second-
ary study outcomes are continuous and will be analyzed
using a similar mixed modeling approach. Rates of all-
cause hospitalization and mortality and the proportion
of patients in each study arm receiving guideline-
concordant care at 12-months will be compared between
study arms using a Chi-Square test. To examine medica-
tion adherence, the PDC for each study group will be
compared as a continuous measure (t-test) and as the
proportion of patients achieving a PDC > 0.80 (Chi-
Square), a cut-off used in multiple medication adherence
studies [25].
Limitations/considerations
It is possible that a given primary care provider will have
patients in both the intervention and control arms and
this will lead to contamination. However, study patients
represent a very small number of the patient panels of a
given primary care provider, and thus the potential for
contamination is low. The intervention is multimodal,
and we may not know the most important components
of the intervention if it is successful. However, as uni-
modal interventions have not been very successful inchanging health care delivery and health status outcomes,
multimodal interventions are necessary [26]. Process mon-
itoring of the intervention through assessment of collab-
orative care team recommendations should provide
insights about important intervention components.
As in many HF studies, we may inadvertently enroll
some patients who do not have HF by criteria such as
Framingham, [14] but this group will be of inherent
interest from the health care system perspective. The ra-
tionale for this inclusive approach is that the study was
designed as an effectiveness trial to support broader im-
plementation if the intervention is successful. We feel it
is important to consider all patients who have a HF diag-
nosis in the medical record and have low HF-specific
health status, above and beyond any physiologic/anatomic
measures (e.g. echo findings) for which is there is no gold-
standard for the diagnosis of HF. Similarly, we believe it
would be wrong to only include patients with systolic dys-
function, since patients with HF and preserved systolic
function are prevalent and also have diminished health
status and poor prognosis [27]. Among enrolled patients,
we will carefully collect and classify medical history and
tests to be able to report the proportions of patients with
and without systolic dysfunction and the etiology of HF.
Discussion
The PCDM trial is unique because it uses a patient-
centered measure for study entry and as the primary
outcome. It employs population-based case finding
methods to target HF patients with diminished self-
reported health status who are at high risk and who
may benefit most from disease management. The
PCDM intervention uses collaborative care to address
both HF and comorbid depression and leverages health
information technology to provide optimal disease man-
agement. The trial builds on previous studies of HF dis-
ease management by prioritizing patient health status,
implementing a collaborative care model of health care
delivery, and addressing depression, a key barrier to op-
timal disease management. The study has been designed
as an ‘effectiveness trial’ to support broader implemen-
tation in the healthcare system if it is successful.
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